调肠克敏颗粒治疗腹泻型肠易激综合征的疗效与适应证优化:随机对照试验研究方案
本研究为平行组、随机、双盲、安慰剂对照试验,嵌入结局预测因素分析,纳入腹泻型肠易激综合征患者,随机分为调肠克敏颗粒组或安慰剂组,均接受健康教育,治疗4周、随访12周。主要结局为 adequate relief(AR)评估的总体改善,次要结局包括至缓解时间、至首次复发时间、总复发次数、长期有效性、个体症状、IBS-SSS、IBS-QOL及HADS。研究旨在提供调肠克敏颗粒疗效与安全性的高质量证据,并优化其适应证。
要点
- 调肠克敏颗粒治疗腹泻型肠易激综合征的随机双盲安慰剂对照试验方案。
- 主要结局为AR评估的总体改善,随访12周关注复发相关指标。
- 嵌入预测因素分析以优化调肠克敏颗粒的适应证人群。
核心结论
- 该试验可能为调肠克敏颗粒治疗IBS提供疗效与安全性的高质量证据,并给出更精确的适应证。
研究设计与样本
- 平行组、随机、双盲、安慰剂对照试验,嵌入结局预测因素。
- 纳入腹泻型肠易激综合征患者,随机分为调肠克敏颗粒组或安慰剂组,均接受健康教育。
- 治疗4周,随访12周。
关键数值与推荐
- 主要结局为AR评估的总体改善。
- 次要结局包括至缓解时间、至首次复发时间、总复发次数、长期有效性、个体症状、IBS-SSS、IBS-QOL及HADS。
- 广泛收集与患者及疾病特征相关的预测因素并嵌入试验以供进一步识别。
临床怎么用
- 若验证有效,可为腹泻型肠易激综合征提供调肠克敏颗粒的治疗选择并明确目标人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Irritable bowel syndrome (IBS) is a chronic, recurring condition, prevalent in the general population. Current medication treatments usually leave patients undertreated. Nowadays, Chinese medicine (CM) is being considered as a promising treatment approach for IBS. However, due to methodological limitations, there is no strong evidence to support CM. Although IBS relapses are common, the relapse assessment has always been neglected in CM study designs. Meanwhile, in clinical practice and studies, it has been found that certain CM formulas can only benefit certain kinds of patients. Discovering what population and illness characteristics likely respond to outcomes may help improve the effectiveness of CM. The aims of this study are to evaluate the efficacy and safety of Tiao-Chang Ke-Min (TCKM) granules for IBS, especially in reducing IBS symptoms' relapse, by a high-quality randomized controlled trial and then to optimize the indication of the TCKM granules. METHODS/DESIGN: This is a parallel-group, randomized, double-blind, placebo-controlled trial embedded with outcome predictive factors. Eligible patients with diarrhea-predominant IBS will be randomized into either a TCKM granule group or a placebo group. Patients from both groups will receive health education. The treatment duration is 4 weeks and the follow-up is 12 weeks. The primary outcome is global improvement measured with adequate relief (AR). The second outcome measures include time until relief, time until first relapse, total relapse times, long-term effectiveness, individual symptoms, IBS-Symptom Severity Score (IBS-SSS), IBS-Quality of Life Questionnaire (IBS-QOL), and Hospital Anxiety and Depression Scale (HADS). Predictive factors associated with patient and illness characteristics have been widely collected. These factors will be embedded in this trial for further identification. DISCUSSION: This trial may provide high-quality evidence on the efficacy and safety of TCKM granules for IBS and a more accurate indication. Importantly, this trial will provide a new research method for improving the therapeutic effects of CM for clinicians and researchers. To address IBS relapse assessment, a series of special definitions of relapse incidents has been made for this trial. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ID: ChiCTR-IOR-17010600 . Registered on 9 February 2017.
引用
- Li Q, Zhang BP, Huang SG, et al. Efficacy and indication optimization of Chinese medicine (Tiao-Chang Ke-Min granules) for diarrhea-predominant irritable bowel syndrome: study protocol for a randomized controlled trial. Trials. 2018. PMID: 29996882. doi:10.1186/s13063-018-2754-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。